469 completed, 90 unknown, 69 terminated, 34 recruiting. 323 Phase 2, 139 Phase 1, 130 Phase 3, 114 Phase 4, 58 Not applicable.
Follow Cyclosporine: new trials by email Literature Review of Cyclosporine trials Research Report on Cyclosporine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants Velzatinib, Cyclosporine, Omeprazole - Healthy Participants, Gastrointestinal Neoplasms | Phase 1 | Not yet recruiting | GlaxoSmithKline | 36 | 2026-10-16 | 2026-10-07 |
| Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy Zuberitamab 1000mg, Cyclosporine - Primary Membranous Nephropathy | Phase 3 | Not yet recruiting | BioRay Pharmaceutical Co., Ltd. | 150 | 2026-10-01 | 2026-09-21 |
| Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Phase 2 | Recruiting | NYU Langone Health | 60 | 2026-10-01 | 2026-10-15 |
| A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood BI 3000202, Ciclosporin, Itraconazole - Healthy | Phase 1 | Active not recruiting | Boehringer Ingelheim | 16 | 2026-09-01 | 2026-10-13 |
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD anti-CD25 rhMAb, Prednisone, Ruxolitinib - cGVHD | Phase 4 | Not yet recruiting | Peking University People's Hospital | 30 | 2026-07-15 | 2026-06-18 |
| TRACK-TBI Precision Medicine Part 3 - Option II Cyclosporine (CsA), Placebo - Traumatic Brain Injury | Phase 2 | Enrolling by invitation | University of California, San Francisco | 26 | 2026-07-02 | 2026-10-22 |
| CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), Thrombopoietin Receptor Agonist, Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA Enarodustat, Cyclosporin (CSA) - Transfusion-dependent Non-severe Aplastic Anemia | Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia rhTPO, Cyclosporine (CsA) - Lower-risk Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 78 | 2026-06-01 | 2026-06-17 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) INCA034176, Best available Treatment (BAT) - Chronic Graft-versus-host-disease | Phase 2 | Recruiting | Incyte Corporation | 60 | 2026-05-20 | 2026-10-09 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA Enarodustat, Cyclosporine (CsA) - Transfusion-dependent Non-severe Aplastic Anemia | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 90 | 2026-04-01 | 2026-04-23 |
| CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), thrombopoietin receptor agonist (TPO-RA), Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 43 | 2026-04-01 | 2026-04-30 |
| A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695 - Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | Recruiting | Laboratoires Thea | 120 | 2026-03-24 | 2026-04-22 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study Cyclosporin - Dry Eye Disease (DED) | Completed | Laboratoires Thea | 25 | 2026-01-20 | 2026-08-14 | |
| A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia Romiplostim N01, Cyclosporine A (CsA), pALG/ rATG - Treatment-naïve Severe Aplastic Anemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 210 | 2026-01-01 | 2026-01-15 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
Showing 20 of 720. Sign in to see all of them.
Leukemia, Myeloid, Acute (101) · Leukemia (98) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (95) · Myelodysplastic Syndromes (91) · Leukemia, Lymphocytic, Chronic, B-Cell (78) · Lymphoma, Non-Hodgkin (76) · Hodgkin Disease (67) · Multiple Myeloma (67) · Lymphoma, Mantle-Cell (63) · Lymphoma (62) · Lymphoma, Large B-Cell, Diffuse (60) · Graft vs Host Disease (59) · Lymphoma, Follicular (59) · Leukemia, Myeloid, Chronic-Phase (57) · Burkitt Lymphoma (53)
Fred Hutchinson Cancer Center (77) · Novartis Pharmaceuticals (31) · National Heart, Lung, and Blood Institute (NHLBI) (20) · Masonic Cancer Center, University of Minnesota (18) · Peking Union Medical College Hospital (14) · Hoffmann-La Roche (12) · Wyeth is now a wholly owned subsidiary of Pfizer (12) · National Cancer Institute (NCI) (11) · Stanford University (10) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · Pfizer (9) · M.D. Anderson Cancer Center (8) · Novartis (8) · Bristol-Myers Squibb (7) · Case Comprehensive Cancer Center (7)
United States (376) · Germany (69) · China (62) · France (50) · Canada (48) · Italy (48) · Spain (34) · Belgium (30) · United Kingdom (27) · Australia (25) · Switzerland (25) · Norway (23) · Netherlands (21) · Sweden (20) · Austria (19)
Brenda Sandmaier (16) · David Maloney (6) · Claudio G. Brunstein, MD, PhD (4) · Danielle M Townsley, M.D. (4) · H. Joachim Deeg, MD (4) · Marco Mielcarek (4)
PMID 32499241, PMID 34724566, PMID 29674506, PMID 34778952, PMID 19179301, PMID 19667400, PMID 20661232, PMID 21403127, PMID 22067384, PMID 22430088, PMID 24831918, PMID 26321103, PMID 27433815, PMID 29958797, PMID 30231851, PMID 36240296, PMID 10221490, PMID 10231138, PMID 10583235, PMID 10798738, PMID 1090310, PMID 12270445, PMID 12411407, PMID 12438948, PMID 12611000, PMID 12622583, PMID 12761269, PMID 12867568, PMID 14742989, PMID 14742990, PMID 15314059, PMID 15352988, PMID 15466923, PMID 15494274, PMID 15660173, PMID 15691277, PMID 15895230, PMID 15899725, PMID 15919463, PMID 16110027, PMID 16192477, PMID 16407509, PMID 16556894, PMID 16570006, PMID 16771810, PMID 17109339, PMID 17192769, PMID 17563739, PMID 17565578, PMID 17889355
P30CA015704 (44), P01CA018029 (14), P01CA078902 (9), 2009 (6), P01CA044991 (5), 2008 (4), 2014 (4), P30CA016672 (4), P30CA043703 (4), U10CA032102 (4), 2005 (3), P01HL036444 (3), P30CA033572 (3), U10CA021115 (3), 2004 (2)